培唑帕尼治疗中国晚期软组织肉瘤的回顾性研究  

A retrospective study:the efficacy and safety of pazopanib treatment in Chinese patients with advanced soft tissue sarcoma

作　　者：徐步舒 郭天慧 刘梦梦 潘求忠 彭瑞清[1] 张星[1] Xu Bushu;Guo Tianhui;Liu Mengmeng;Pan Qiuzhong;Peng Ruiqing;Zhang Xing(Melanoma and Sarcoma Medical Oncology Unit,Sun Yat-sen University Cancer Center/State Key Laboratory of Oncology in South China,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心黑色素瘤与肉瘤内科/华南肿瘤学国家重点实验室,广州510060

出　　处：《中华转移性肿瘤杂志》2021年第2期82-86,共5页Chinese Journal of Metastatic Cancer

摘　　要：目的探索培唑帕尼治疗中国晚期软组织肉瘤(STS)患者的有效性及安全性。方法收集2017—2018年间在中山大学肿瘤防治中心就诊的58例晚期STS患者使用培唑帕尼的临床特征、生存预后及疗效等资料进行回顾性分析。结果所有患者均使用了培唑帕尼治疗,其中11例患者以培唑帕尼治疗作为一线治疗(19%),24例患者作为二线治疗(41%),23例患者作为三线及以上治疗(40%)。总体最佳客观缓解率为31%,疾病缓解率为76%,中位无进展生存期为5.1个月(95%CI为3.7~6.5),中位总生存期为13.3个月(95%CI为8.0~18.7)。主要不良反应为毛发变白(95%)及手足综合征(83%),大部分不良反应为轻度及中度。结论培唑帕尼对中国晚期STS人群有效且毒性可耐受,部分不良反应及严重程度等表现出中国患者特征。Objective To investigate the efficacy and safety of pazopanib on advanced soft tissue sarcoma(STS)in China.Methods The clinical features,survival prognosis and efficacy of pezopani were collected and retrospectively analyzed from 58 patients who were treated in the Cancer Prevention and Treatment Center of Zhongshan University from 2017 to 2018.Results All patients were treated with pezoparib,including 11 patients treated with pezoparib as the first-line treatment(19%),24 patients as the second-line treatment(41%),23 patients as the third-line and above treatment(40%).The overall objective response rate was 31%,the disease control rate was 76%,and the median progression-free survival time was 5.1 months(95%CI:3.7~6.5),the median overall survival time was 13.3 months(95%CI:8.0~18.7).The most common adverse events were hair hypopigmentation(95%)and palmar-plantar erythrodysaesthesia syndrome(83%).The majority of adverse events were mild or modest.Conclusions The effects of pazopanib treatment in Chinese STS patients were significant.Pazopanib-related toxicity was tolerable.Some adverse events and the severity exhibited the features of Chinese cases.

关 键 词：培唑帕尼 软组织肉瘤 中国患者 有效性及安全性 

分 类 号：R73[医药卫生—肿瘤]